Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan;28(1):253-256.
doi: 10.3201/eid2801.204809. Epub 2021 Dec 2.

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Nicolas Lambert, Solène Dauby, Dominique Dive, Bernard Sadzot, Pierre Maquet
Case Reports

Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy

Nicolas Lambert et al. Emerg Infect Dis. 2022 Jan.

Abstract

Atezolizumab successfully reinvigorated JC virus immunity in a patient in Belgium with progressive multifocal leukoencephalopathy, as demonstrated by clinical, virologic, and radiologic response to treatment. However, the treatment also resulted in immune reconstitution inflammatory syndrome and life-threatening immune-related adverse events. These conditions were treated with corticosteroids, leading to treatment resistance.

Keywords: Belgium; JC virus; atezolizumab; immune reconstitution inflammatory syndrome; immunotherapy; progressive multifocal leukoencephalopathy; viruses.

PubMed Disclaimer

Figures

Figure
Figure
Clinical course and evolution of JC virus load in CSF of 77-year-old patient undergoing atezolizumab therapy for progressive multifocal leukoencephalopathy. CSF, cerebrospinal fluid; IRAEs, immune-related adverse events; JCV, JC virus.
See this image and copyright information in PMC

References

    1. Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37–51. 10.1038/s41582-020-00427-y - DOI - PMC - PubMed
    1. Beck ES, Cortese I. Checkpoint inhibitors for the treatment of JC virus-related progressive multifocal leukoencephalopathy. Curr Opin Virol. 2020;40:19–27. 10.1016/j.coviro.2020.02.005 - DOI - PubMed
    1. Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–8. 10.1212/WNL.0b013e31828c2fa1 - DOI - PMC - PubMed
    1. Antoniol C, Jilek S, Schluep M, Mercier N, Canales M, Le Goff G, et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management? Neurology. 2012;79:2258–64. 10.1212/WNL.0b013e3182768983 - DOI - PubMed
    1. Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, et al. Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. J Exp Med. 2019;216:2701–13. 10.1084/jem.20190738 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances